Novaquest Capital Management appeared to be the VC, which was created in 2010. The company was established in North America in United States. The main department of described VC is located in the Raleigh.
The higher amount of exits for fund were in 2014. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The typical startup value when the investment from Novaquest Capital Management is more than 1 billion dollars. This Novaquest Capital Management works on 11 percentage points more the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 40 percentage points more often commits exit comparing to other companies.
The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Roivant Sciences, PreCision Dermatology, Clinical Ink. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical, Health Care.
We also calculated 10 valuable employees in our database.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Novaquest Capital Management, startups are often financed by FCA Venture Partners, Viking Global Investors, SoftBank Investment Advisers. The meaningful sponsors for the fund in investment in the same round are Viking Global Investors, TT Capital Partners, SoftBank Investment Advisers. In the next rounds fund is usually obtained by Silicon Valley Bank, RTI International, CIBC.
Funds with similar focus
|Alumot VC||Israel, Tel Aviv, Tel Aviv District|
|Anhui Zhongding Sealing Parts||Anhui, China, Ningguo|
|Anzu Partners||District of Columbia, United States, Washington|
|Aurec Group||Israel, Ramat Gan, Tel Aviv|
|CYTS||California, San Francisco, United States|
|Dropbox||California, San Francisco, United States|
|GENTOSHA MediaConsulting||Japan, Tokyo|
|o3 Capital||India, Maharashtra, Mumbai|
|Ontario Media Development Corporation||Canada, Ontario, Toronto|
|Pathfinder||California, San Francisco, United States|
|Pengle Network Technology||Beijing, Beijing, China|
|Shanxi Heling Touzi guanli Co., Ltd.||China, Shaanxi, Xian Shi|
|SIIF||Chiba, Japan, Minato|
|SPD International||Australia, Melbourne, Victoria|
|Squadron Medical Finance Solutions||-|
|Start Capital||England, London, United Kingdom|
|Tethys Investment Management||Cambridge, Massachusetts, United States|
|TinkBig Venture||Kuala Lumpur, Malaysia|
|$70M||18 Jul 2022||Lund, Skane Lan, Sweden|
Applied LifeSciences & Systems
|$35M||25 May 2022||North Carolina, United States|
|$160M||07 Jun 2021||Basel, Basel-Stadt, Switzerland|
|$35M||03 May 2021||Durham, North Carolina, United States|
|$20M||19 Oct 2020||North District|
|$42M||27 May 2020||Basel, Basel-City, Switzerland|
|24 Dec 2019||Saint Petersburg, Florida, United States|
|$50M||18 Jun 2019||Bridgewater, New Jersey, United States|
|$200M||13 Nov 2018||New York, New York, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.